Travere Therapeutics Deal History & Licensing Activity
Travere Therapeutics is a biotech headquartered in US. Over the past three years, Travere Therapeutics has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 13 active clinical trials, primarily in Immunology.
Deals (12mo)
2
Active Trials
13
Top Modality
Small Molecules
Focus Area
Immunology
Travere Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Travere Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| civorebrutinib (EVER001) | Travere | Small Molecules | Phase 2 | license | Jun 2026 |
| civorebrutinib (EVER001) | Everest Medicines | Small Molecules | Phase 2 | license | Jun 2026 |
Travere Therapeutics Pipeline Focus
Therapeutic areas and modalities where Travere Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Travere Therapeutics Strategic Signals
Key indicators of Travere Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Travere Therapeutics Clinical Pipeline
Travere Therapeutics has 13 active clinical trials across 6 development phases.
1
Phase 4
1
Not Applicable
2
Unknown
2
Phase 1
3
Phase 2
4
Phase 3
See How Your Asset Matches Travere Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Travere Therapeutics Licensing & Deal Activity
Travere Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Travere Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Travere Therapeutics include Immunology (4 deals and trials), Autoimmune (3 deals and trials), Mega Deals (1 deal and trial), and CNS Disorders (1 deal and trial). In terms of modality, Travere Therapeutics has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Travere Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Travere Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.